<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05044871</url>
  </required_header>
  <id_info>
    <org_study_id>2021-TJ-PROC</org_study_id>
    <nct_id>NCT05044871</nct_id>
  </id_info>
  <brief_title>Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer</brief_title>
  <acronym>BRIGHT</acronym>
  <official_title>The Efficiency of Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer (PROC): An Umbrella Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hubei Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Obstetrics and Gynecology Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jilin Provincial Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Jiangnan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, multicenter, umbrella study aimed to evaluate the combined,&#xD;
      biomarker-driven, targeted treatment efficiency of Pamiparib, Bevacizumab, Tislelizumab, and&#xD;
      Nab-paclitaxel in patients with platinum-resistant recurrent ovarian cancer (PROC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BRCA1/2 gene status and CD8+ tumor-infiltrating T cell count (CD8 + TILs count) were&#xD;
      evaluated as biomarkers using archived tumor tissue samples. Treatment arms were arranged&#xD;
      according to pathological diagnosis and biomarker detection results.&#xD;
&#xD;
      Arm1 (Pathological classification: Serous, Endometrioid, and Clear cell Ovarian cancer;&#xD;
      Biomarkers: BRCA 1/2 mutant): Pamiparib 40mg PO. bid. plus Bevacizumab 7.5mg/kg IV. D1&#xD;
      (q3w.).&#xD;
&#xD;
      Arm2 (Pathological classification: Serous, Endometrioid, and Clear cell Ovarian cancer;&#xD;
      Biomarkers: BRCA 1/2 wildtype and ≥3 CD8+ TILs count): Tislelizumab 200mg IV. D1 +&#xD;
      Bevacizumab 7.5mg/kg IV. D1 + Nab-paclitaxel 125mg / m2 IV. D1, 8 (q3w).&#xD;
&#xD;
      Arm3 (Pathological classification: Serous, Endometrioid, and Clear cell Ovarian cancer;&#xD;
      Biomarkers: BRCA 1/2 wildtype and &lt;3 CD8+ TILs count): Bevacizumab 7.5mg/kg IV D1, 15 +&#xD;
      Nab-paclitaxel 100mg / m2 IV D1, 8, 15 (Q4w).&#xD;
&#xD;
      Arm4 (Pathological classification: Mucinous Ovarian cancer, Ovarian carcinosarcoma;&#xD;
      Biomarkers: ≥3 CD8+ TILs count): Tislelizumab 200mg IV D1 + Bevacizumab 7.5mg/kg IV D1 +&#xD;
      Nab-paclitaxel 125mg / m2 IV D1, 8 (q3w).&#xD;
&#xD;
      Arm5 (Pathological classification: Mucinous Ovarian cancer, Ovarian carcinosarcoma;&#xD;
      Biomarkers: &lt;3 CD8+ TILs count: Bevacizumab 7.5mg/kg IV. D1, 15 + Nab-paclitaxel 100mg / m2&#xD;
      IV. D1, 8, 15 (Q4w).&#xD;
&#xD;
      Treatment would continue until disease progression, intolerable toxicity, death, withdrawal&#xD;
      of consent, or sponsor termination of the study, whichever occurs first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>ORR is defined as the proportion of patients with complete response(CR) and partial response(PR) assessed by the investigator in accordance with the RECIST 1.1 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>PFS is defined as the time from enrollment to the first imaging disease progression or death (whichever occurs first). Assessed according to RECIST v1.1 by investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>OS is defined as the time between enrollment and the patient's death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>DCR is defined as the proportion of the patients with complete response, partial remission, and stable disease after treatment. Assessed according to RECIST v1.1 by investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission (DOR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>DOR is defined as the time interval from the first record of disease response to disease progression or death (whichever occurs first). Assessed according to RECIST v1.1 by investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Safety includes the adverse event profile of all drugs included according to the Common Terminology Criteria for Adverse Events version 5.0.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1: Pamiparib+ Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm1 (Pathological classification: Serous, Endometrioid, and Clear cell Ovarian cancer; Biomarkers: BRCA 1/2 mutant): Pamiparib 40mg PO. bid. plus Bevacizumab 7.5mg/kg IV. D1 (q3w.).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Tislelizumab + Bevacizumab + Nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm2 (Pathological classification: Serous, Endometrioid, and Clear cell Ovarian cancer; Biomarkers: BRCA 1/2 wildtype and ≥3 CD8+ TILs count): Tislelizumab 200mg IV. D1 + Bevacizumab 7.5mg/kg IV. D1 + Nab-paclitaxel 125mg / m2 IV. D1, 8 (q3w).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Bevacizumab + Nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm3 (Pathological classification: Serous, Endometrioid, and Clear cell Ovarian cancer; Biomarkers: BRCA 1/2 wildtype and &lt;3 CD8+ TILs count): Bevacizumab 7.5mg/kg IV D1, 15 + Nab-paclitaxel 100mg / m2 IV D1, 8, 15 (Q4w).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: Tislelizumab + Bevacizumab + Nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm4 (Pathological classification: Mucinous Ovarian cancer, Ovarian carcinosarcoma; Biomarkers: ≥3 CD8+ TILs count): Tislelizumab 200mg IV D1 + Bevacizumab 7.5mg/kg IV D1 + Nab-paclitaxel 125mg / m2 IV D1, 8 (q3w).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5: Bevacizumab + Nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm5 (Pathological classification: Mucinous Ovarian cancer, Ovarian carcinosarcoma; Biomarkers: &lt;3 CD8+ TILs count: Bevacizumab 7.5mg/kg IV. D1, 15 + Nab-paclitaxel 100mg / m2 IV. D1, 8, 15 (Q4w).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pamiparib</intervention_name>
    <description>40mg PO. bid.</description>
    <arm_group_label>Arm 1: Pamiparib+ Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>7.5mg/kg IV. D1 (q3w.)</description>
    <arm_group_label>Arm 1: Pamiparib+ Bevacizumab</arm_group_label>
    <arm_group_label>Arm 2: Tislelizumab + Bevacizumab + Nab-paclitaxel</arm_group_label>
    <arm_group_label>Arm 4: Tislelizumab + Bevacizumab + Nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>200mg IV. D1</description>
    <arm_group_label>Arm 2: Tislelizumab + Bevacizumab + Nab-paclitaxel</arm_group_label>
    <arm_group_label>Arm 4: Tislelizumab + Bevacizumab + Nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab paclitaxel</intervention_name>
    <description>125mg / m2 IV. D1, 8 (q3w).</description>
    <arm_group_label>Arm 2: Tislelizumab + Bevacizumab + Nab-paclitaxel</arm_group_label>
    <arm_group_label>Arm 4: Tislelizumab + Bevacizumab + Nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab + Nab paclitaxel (intense dose-dense)</intervention_name>
    <description>Bevacizumab 7.5mg/kg IV. D1, 15 (Q4w). + Nab paclitaxel 100mg / m2 IV. D1, 8, 15 (Q4w).</description>
    <arm_group_label>Arm 3: Bevacizumab + Nab-paclitaxel</arm_group_label>
    <arm_group_label>Arm 5: Bevacizumab + Nab-paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary participation and signing of informed consent&#xD;
&#xD;
          2. Age ≥ 18 years;&#xD;
&#xD;
          3. the Eastern United States cancer cooperation group (ECoG) score 0-1;&#xD;
&#xD;
          4. Platinum-resistant recurrent ovarian cancer (PROC): the patient was diagnosed with&#xD;
             platinum-resistant recurrence for the first time. PROC refers to the disease&#xD;
             progression that occurred &lt; 6 months after the last dose of platinum-based&#xD;
             chemotherapy. Imaging-based evaluation for the latest recurrence/progression before&#xD;
             enrollment was required;&#xD;
&#xD;
          5. Malignant epithelial ovarian cancer, fallopian tube cancer or primary peritoneal&#xD;
             cancer confirmed by histology or cytology, including high-grade serous cancer,&#xD;
             low-grade serous cancer, endometrioid cancer, clear cell cancer, mucinous cancer, and&#xD;
             carcinosarcoma;&#xD;
&#xD;
          6. Biomarker detection and tumor sample collection meet the following standards:&#xD;
&#xD;
               -  Patients must provide archived tumor tissue samples (formalin-fixed,&#xD;
                  paraffin-embedded tumor tissue blocks [preferred], or about 20 unstained tissue&#xD;
                  sections), except for patients with serous carcinoma, endometrioid carcinoma,&#xD;
                  clear cell carcinoma and gBRCAm&#xD;
&#xD;
               -  If the patient has been tested for BRCA1 / 2 gene in the past, only the&#xD;
                  corresponding test report needs to be provided&#xD;
&#xD;
          7. Sufficient organ functions, which is defined as:&#xD;
&#xD;
               -  neutrophil absolute value (ANC) ≥ 1.5 × 109/L&#xD;
&#xD;
               -  platelet count (PLT) ≥ 75 × 10*9/L&#xD;
&#xD;
               -  hemoglobin ≥ 9 g / dl&#xD;
&#xD;
               -  serum creatinine CR &lt; 1.5 × Upper normal value (ULN)&#xD;
&#xD;
               -  total serum bilirubin ≤ 1.5 × Upper normal range (ULN)&#xD;
&#xD;
               -  both aspartate aminotransferase and alanine aminotransferase ≤ 3 × ULN&#xD;
&#xD;
               -  coagulation function: international normalized ratio (INR) ≤ 1.5; Activated&#xD;
                  partial prothrombin time (APTT) ≤ 1.5 × ULN&#xD;
&#xD;
          8. Patients must have lesions that can be measured according to RECIST v1.1 standard;&#xD;
&#xD;
          9. Participants were allowed to have previously VEGF / VEGFR inhibitors treatment, but&#xD;
             the proportion of these patients would not exceed 20%;&#xD;
&#xD;
         10. Participants were allowed to have previously PARP inhibitors treatment. However, for&#xD;
             treatment arm 1 (arm1), the exposure time of PARP inhibitors should ≥ 12 months after&#xD;
             first-line chemotherapy or ≥ 6 months after second-line and above chemotherapy;&#xD;
&#xD;
         11. Life expectancy ≥ 3 months;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The exclusion criteria of bevacizumab were clinically significant cardiovascular and&#xD;
             cerebrovascular diseases, history of abdominal fistula or gastrointestinal&#xD;
             perforation, acute intestinal obstruction or sub obstruction, and active bleeding;&#xD;
&#xD;
          2. Uncontrolled hypertension (systolic blood pressure &gt; 150 mmHg and/or diastolic blood&#xD;
             pressure &gt; 100 mmHg) or clinically significant (active) cardiovascular disease:&#xD;
             cerebrovascular accident (CVA) / stroke ≤ 6 months from the treatment of the first&#xD;
             clinical study; Myocardial infarction ≤ 6 months from the first clinical study&#xD;
             treatment; Unstable angina pectoris; Congestive heart failure (CHF) of grade II or&#xD;
             above in the cardiac function classification standard of the New York Heart&#xD;
             Association (NYHA); Serious arrhythmias requiring treatment;&#xD;
&#xD;
          3. Previous medical history showed newly discovered thrombotic diseases within 6 months&#xD;
             before or during the screening period; Patients with severe wound nonunion, ulcer, or&#xD;
             fracture;&#xD;
&#xD;
          4. Major surgery within 30 days before the first administration of study treatment;&#xD;
             Patients expected to have invasive surgery during treatment;&#xD;
&#xD;
          5. Patients with other malignant tumors;&#xD;
&#xD;
          6. Patients who have previously received anti-programmed cell death protein-1&#xD;
             (anti-PD-1), anti-programmed death ligand-1 (anti-PD-L1) or anti-PD-L2 drugs, or&#xD;
             another drug treatment for T cell inhibitory receptors (e.g., cytotoxic T&#xD;
             lymphocyte-associated antigen-4 [CTLA-4], OX-40, CD137 [tumor necrosis factor receptor&#xD;
             superfamily member 9 (tnfrsf9)];&#xD;
&#xD;
          7. Active autoimmune diseases requiring systemic treatment in the past 2 years;&#xD;
&#xD;
          8. Any case requiring systemic treatment with corticosteroids (prednisone or equivalent &gt;&#xD;
             10 mg/day) or other immunosuppressive drugs ≤ 14 days before the first administration&#xD;
             of the study drug;&#xD;
&#xD;
          9. Known history of human immunodeficiency virus (HIV) infection;&#xD;
&#xD;
         10. Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers (HBV DNA &gt;&#xD;
             500 IU / ml) or active HCV carriers with detectable HCV RNA; Note: inactive hepatitis&#xD;
             B surface antigen (HBsAg) carriers and treated and stable hepatitis B patients (HBV&#xD;
             DNA &lt; 500 IU / ml) can be included in the group;&#xD;
&#xD;
         11. History of interstitial lung disease, noninfectious pneumonia, or uncontrolled&#xD;
             diseases, including pulmonary fibrosis, acute lung disease, etc;&#xD;
&#xD;
         12. Previous heterologous stem cell transplantation or organ transplantation;&#xD;
&#xD;
         13. Peripheral neuropathy ≥ grade 2;&#xD;
&#xD;
         14. Foods or drugs that are expected to use CYP3A4 strong inducers or strong inhibitors&#xD;
             within 28 days before the use of the study drug;&#xD;
&#xD;
         15. Participate in another clinical study at the same time, unless it is an observational&#xD;
             (non-intervention) clinical study or is in the follow-up period of intervention study;&#xD;
&#xD;
         16. Women of childbearing age who are unwilling or unable to use effective methods for&#xD;
             contraception during the whole treatment period of this trial and within 6 months&#xD;
             after the last administration of the study drug [women of childbearing age include:&#xD;
             any women who have had menarche and have not undergone successful artificial&#xD;
             sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), or&#xD;
             premenopausal], pregnant or lactating women.&#xD;
&#xD;
         17. Other conditions judged by the researcher that do not meet the enrollment&#xD;
             requirements.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qinglei Gao, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qinglei Gao, MD. PhD</last_name>
    <phone>15391566981</phone>
    <email>qingleigao@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Qinglei Gao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Biomarker-driven</keyword>
  <keyword>Targeted therapy</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

